07:00 , Sep 28, 2015 |  BioCentury  |  Regulation

Serving nerves

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression...